Regulatory T cell depletion via Fc gamma receptor engagement (null)

"Regulatory T cell depletion via Fc gamma receptor engagement" describes a therapeutic strategy rather than a single molecular target. It refers specifically to using monoclonal antibodies—often directed against surface proteins highly expressed by regulatory T cells such as CD25, CTLA‑4, GITR, or TIGIT—that are engineered for optimal interaction between their constant region (Fc) and activating types of human/murine **Fc gamma receptors (FcγRs)** found on innate immune effectors like macrophages and NK cells. This interaction triggers ADCC/ADCP-mediated elimination predominantly within tumors where these targets are most highly expressed by infiltrating regulatory T cells. The approach aims to shift the balance toward antitumor immunity by reducing local immunosuppression but carries risks if systemic tolerance is compromised. Note regarding correctness This entry does not refer directly to a canonical molecule/receptor but rather describes an immunotherapeutic mechanism involving multiple possible targets and effectors. For structured databases focused strictly on molecular entities, this should be flagged as incorrect (`is_incorrect:true`) because it does not correspond uniquely or specifically enough for standard target annotation; instead, it represents a class/mechanism involving several molecules/proteins depending on context ([see sources above]).

Other names

Treg depletion via FcγR engagementRegulatory T cell (Treg) depletion through Fc gamma receptorAntibody-mediated Treg depletion (via FcγR)

Antibodies engineered to bind activating Fc gamma receptors on immune effector cells mediate the selective **depletion of regulatory T cells**, primarily within the tumor microenvironment. This occurs through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), leading to increased ratios of effector to regulatory T cells and improved antitumor responses[1][2][3][4].